logo-loader
viewBiocept Inc

Biocept's liquid biopsy tests now available to detect cancer biomarkers in cerebrospinal fluid; shares spike

The presence of tumor cells in the fluid may be an indicator of brain metastases

Biocept Inc - Biocept Inc’s Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid
Up to 30% and 36% of patients diagnosed with breast and lung cancer, respectively, will develop brain metastases

Biocept Inc’s (NASDAQ:BIOC) Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid, the company announced Tuesday. 

Following the news, the San Diego company's stock jumped 20% to $0.36 a share in New York. 

Physicians can use the assays to evaluate the brain and spinal fluid of their patients for the presence of circulating tumor cells (CTCs) and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system (CNS) metastases, the company said in a statement.

READ: Biocept wins US Patent for its liquid biopsy cancer testing technology

The presence of tumor cells in cerebrospinal fluid (CSF) may be an indicator of brain metastases, which occurs when cancer has spread into the CNS. Up to 30% and 36% of patients diagnosed with breast and lung cancer, respectively, will develop brain metastases.

"Testing the CSF for cancer biomarkers in patients suspected to have brain metastases can be important, as the rapid confirmation and characterization of CNS involvement enables appropriate treatment selection in a timely manner," said Dr Santosh Kesari of the Pacific Neuroscience Institute and John Wayne Cancer Institute.

"Liquid biopsy tests offer the ability to analyze an additional specimen type, beyond blood, to help physicians identify biomarkers and hence inform clinical decision making."

Biocept CEO Michael Nall said: "We are very pleased to make our Target Selector platform available for testing CSF, as a more-rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer.

“Among the significant capabilities of our technology is its versatility, which enables applications in a variety of clinical situations and for use with multiple types of biofluids."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 0.6565 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $86.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Biocept to provide coronavirus test kits, will cover out-of-network patients...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO Tim Kennedy tell Proactive the California-based firm has solved supply chain problems of obtaining 10,000 testing kits to provide coronavirus test to patients. Separately, Nall says the firm has agreed to a managed care provider agreement with...

6 days, 7 hours ago

2 min read